An expert panel report summarized the current state of the art in arrhythmogenic cardiomyopathies, addressing pathogenesis, disease terminology, clinical management, and future research priorities.
Provides an updated expert consensus on the definition, pathogenesis, terminology, and clinical management of arrhythmogenic cardiomyopathy.
It is 35 years since the first description of arrhythmogenic right ventricular cardiomyopathy (ARVC) and more than 20 years since the first reports establishing desmosomal gene mutations as a major cause of the disease. Early advances in the understanding of the clinical, pathological and genetic architecture of ARVC resulted in consensus diagnostic criteria, which proved to be sensitive but not entirely specific for the disease. In more recent years, clinical and genetic data from families and the recognition of a much broader spectrum of structural disorders affecting both ventricles and associated with a propensity to ventricular arrhythmia have raised many questions about pathogenesis, disease terminology and clinical management. In this paper, we present the conclusions of an expert round table that aimed to summarise the current state of the art in arrhythmogenic cardiomyopathies and to define future research priorities.
Elliott et al. (Tue,) conducted a review in Arrhythmogenic Cardiomyopathy. An expert panel report summarized the current state of the art in arrhythmogenic cardiomyopathies, addressing pathogenesis, disease terminology, clinical management, and future research priorities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: